Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032406 · ClinicalTrials.gov registry record · Phase 2
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
A Phase 2 study of Breast Cancer Stage IIB, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT03032406 is a Phase 2 study of Breast Cancer Stage IIB that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 53 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03032406, a Phase 2 study of Breast Cancer Stage IIB, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Hydroxychloroquine
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03032406
The ClinicalTrials.gov registry entry for NCT03032406 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Stage IIB appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT03032406 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03032406 about?
NCT03032406 is a clinical study titled "CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer". To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
What is the current status of trial NCT03032406?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-01-23. Estimated completion is 2026-01-01.
What conditions does trial NCT03032406 study?
This clinical trial studies the following conditions: Breast Cancer Stage IIB.
What interventions are being tested in trial NCT03032406?
The interventions under investigation include: Everolimus (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT03032406?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03032406 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.